Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$27.00
$26.90
$9.83
▼
$27.00
$1.44B-0.123.07 million shsN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$37.62
+0.6%		$44.88
$33.38
▼
$72.66
$3.51B0.61.56 million shs2.37 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
0.00%0.00%0.00%0.00%+147.48%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+0.56%+5.17%-1.05%-41.23%-10.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$27.00
$26.90
$9.83
▼
$27.00
$1.44B-0.123.07 million shsN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$37.62
+0.6%		$44.88
$33.38
▼
$72.66
$3.51B0.61.56 million shs2.37 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
0.00%0.00%0.00%0.00%+147.48%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+0.56%+5.17%-1.05%-41.23%-10.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
2.22
Hold$33.2523.15% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.87
Moderate Buy$70.1486.45% Upside

Current Analyst Ratings Breakdown

Latest XENE and KALV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$73.00
10/2/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/28/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$90.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$69.00 ➝ $64.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$90.00 ➝ $46.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$90.00 ➝ $46.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$81.00 ➝ $70.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$71.00 ➝ $55.00
9/18/2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$97.00 ➝ $90.00
(Data available from 11/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$1.43M1,008.07N/AN/A$2.71 per share9.96
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M484.90N/AN/A$7.53 per share5.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$109.52M-$3.46N/A36.00N/AN/A-341.44%-111.94%N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.74N/AN/AN/AN/A-43.98%-41.72%11/9/2026 (Estimated)

Latest XENE and KALV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.13N/AN/AN/A$1.33 millionN/A
8/6/2026Q2 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.16-$1.11+$0.05-$1.11$1.67 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
8.18
5.17
5.10
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
21.01
21.02

Institutional Ownership

CompanyInstitutional Ownership
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
4.30%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
10053.24 million50.95 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
36496.67 million93.85 millionOptionable

Recent News About These Companies

Xenon to Report Third-Quarter 2026 Results November 9
November 2 at 8:53 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xenon-to-report-third-quarter-2026-results-november-9
Xenon to Report Q3 2026 Financial Results on November 9, 2026
November 2 at 4:01 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/02/3393707/33485/en/xenon-to-report-q3-2026-financial-results-on-november-9-2026.html
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 30, 2026  |  financialpost.comF
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/30/3392624/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Xenon Reports Promising Pain Data, Targets Phase 2 Trials For Two Drug Candidates
October 29, 2026  |  rttnews.comhttps://www.rttnews.com/3705652/xenon-reports-promising-pain-data-targets-phase-2-trials-for-two-drug-candidates.aspx
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
October 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391282/33485/en/xenon-announces-positive-phase-1-and-new-preclinical-data-at-iasp-2026-supporting-advancement-of-xen1701-and-xen1120-to-phase-2-proof-of-concept-studies-in-acute-pain.html
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Has Consensus Target Price of $70.14 According to Analysts
October 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31162817
Xenon Pharmaceuticals (XENE) Expected to Announce Earnings on Monday
October 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31158069
Xenon Pharmaceuticals (XENE) Set to Post Quarterly Earnings on Monday
October 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-xenon-pharmaceuticals-xene-set-to-post-quarterly-earnings-on-monday-2026-10-26/
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385058/1453/en/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors.html
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
October 15, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3008856/xene-s-depression-trial-setback-is-its-pipeline-still-attractive?cid=cs-stocknewsapi-ft-analyst_blog|zer_report_update-3008856
Bank of America Securities Sticks to Their Buy Rating for Xenon (XENE)
October 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XENE-Q/pressreleases/6740944/bank-of-america-securities-sticks-to-their-buy-rating-for-xenon-xene/
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month Low - Here's Why
October 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-hits-new-12-month-low-heres-why-2026-10-13/
Xenon Pharmaceuticals (NASDAQ:XENE) Cut to "Strong Sell" at Wall Street Zen
October 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-xenon-pharmaceuticals-nasdaq-xene-cut-to-strong-sell-at-wall-street-zen-2026-10-11/
Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-xenon-pharmaceuticals-xene-getting-231010016.html
Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
October 9, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/xenon-pharmaceuticals-xene-stock-may-141401053.html
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376617/1453/en/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors.html
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low - Here's Why
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-xenon-pharmaceuticals-nasdaq-xene-sets-new-1-year-low-heres-why-2026-10-06/
Guggenheim Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-guggenheim-reaffirms-buy-rating-for-xenon-pharmaceuticals-nasdaq-xene-2026-10-06/
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026
October 5, 2026  |  biospace.comB
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026  |  financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

KalVista Pharmaceuticals stock logo

KalVista Pharmaceuticals NASDAQ:KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$37.62 +0.21 (+0.56%)
Closing price 11/2/2026 04:00 PM Eastern
Extended Trading
$37.84 +0.22 (+0.58%)
As of 08:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas